Hi everybody. Tune in to this short version of the podcast, which we do every Friday for the long

version. Tune in on Wednesdays.

Hi everyone. I'm Nicola Tangan, the CEO of the Norwegian sovereign wealth fund. And today I'm in

really good company with Emma Wormsley, the CEO of GSK, one of the global leaders in pharmaceuticals. Now, we own 1.7% of GSK valued at 1.3 billion

US dollars. Emma, great to have you here. Wonderful to be here. Thanks for him.

I believe this is the second podcast ever in your life. The second ever. Wow. Looking forward

very much to the conversation. Now, which areas of research excites you the most just now?

What excites me most is when we can innovate in a way that has real impact at scale

for patients around the world.

So I'm incredibly excited about five new approvals for new drugs and vaccines that

we're expecting to get this

year, one down and another four to go. And that's the first wave of a cohort of, we think,

14 scale medicines and vaccines, each of the potential of more than two billion pounds worth

of sales that we expect to launch this decade. And that includes in areas of

oncology, in infectious diseases, in respiratory immunology, in HIV. And, you know, some of these,

what's really exciting is when you have totally new technology platforms in pharmaceuticals. So,

for example, in multiple myeloma, very nasty blood cancer that, where there are 180,000

new diagnoses every year, we have a new technology platform, something called antibody drug

conjugates.

And you have to think of these as like kind of biological missiles that have precision targeting for cancer, which means they can bring greater

efficacy, but also with less side effects. So we hopefully have a new multiple myeloma drug

that has data that proves it extends life expectancy by three years. That's a very big deal for

...